c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Deuremidevir for COVID-19: real-time meta-analysis of 2 studies

@CovidAnalysis, November 2026, Version 1V1

Deuremidevir COVID-19 outcomes

c19early.org
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Shen11%0.89 · 0.79–1.01viral time60 (n)76 (n) Shen23%0.77 · 0.66–0.90viral time32 (n)76 (n) Shen−3%1.03 · 0.89–1.19viral time28 (n)76 (n) Fan (DB RCT)67%0.33 · 0.01–8.18severe case0/6461/650 Fan (DB RCT)15%0.85 · 0.75–0.96recovery646 (n)650 (n) Fan (DB RCT)14%0.86 · 0.70–1.05no recov.133/646156/650 Fan (DB RCT)24%0.76 · 0.63–0.93viral load99 (n)107 (n)
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Deuremidevir
reduces riskDeuremidevir
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.